Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 9/20 | 0.39 |
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | MMP3 | P08254 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759345 | 0.91 | KISS1R (0.44) | KISS1RRENMMP12OPRD1OPRM1 | |
| SCHEMBL30759554 | 0.91 | KISS1R (0.41) | KISS1RRENMMP12OPRD1OPRM1 | |
| SCHEMBL31754278 | 0.89 | KISS1R (0.39) | KISS1RRENOPRD1OPRM1MMP2 | |
| SCHEMBL30759439 | 0.88 | KISS1R (0.41) | KISS1RRENMMP12OPRD1OPRM1 | |
| SCHEMBL30759468 | 0.87 | OPRM1 (0.45) | OPRD1OPRM1MMP2MMP1MMP3 | |
| SCHEMBL30759443 | 0.86 | KISS1R (0.45) | KISS1RREN | |
| SCHEMBL30759397 | 0.86 | REN (0.40) | RENOPRD1OPRM1MMP2MMP1 | |
| SCHEMBL30759527 | 0.85 | OPRM1 (0.39) | KISS1RMMP12OPRD1OPRM1MMP2 | |
| SCHEMBL30759473 | 0.83 | MMP2 (0.43) | MMP2MMP1MMP3GNPAT | |
| SCHEMBL31754333 | 0.83 | LONP1 (0.38) | MMP12MMP2MMP1MMP3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | KISS1R 2731/4885REN 186/4885MMP12 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.